Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What Two FDA Decision Dates Could Mean for FTSE 100 Drugmaker GSK (LSE:GSK)

Drug companies live by two calendars. One is the financial calendar of results, dividends and guidance. The other is the regulatory calendar, where a single decision can shape a product's prospects for a decade. For GSK (LSE:GSK), one of the largest companies in the …

Ankur Sharma | 12 October 2026

Why Is Genetic Prevention Pioneer GENinCode PLC (LSE:GENI) Attracting Global Healthcare Attention?

Cardiovascular disease (CVD) remains the single largest cause of mortality globally, claiming approximately 18 million lives annually and costing healthcare systems hundreds of billions of pounds in emergency hospitalisations and acute interventions. For decades, clinical physicians have relied on traditional risk calculators—measuring cholesterol, blood …

Ankur Sharma | 12 October 2026

Why Reckitt (LSE:RKT) Still Sits Around 22% Below Its February FTSE 100 Peak

Reckitt (LSE:RKT) has had a year of two halves. The FTSE 100 consumer goods group set a 2026 closing high of 6,512p on 27 February, then slid to a closing low of 4,443p on 2 June. On the morning of Wednesday 7 October, the …

Ankur Sharma | 12 October 2026

Why Budget Day Is Also Results Day for Unilever (LSE:ULVR) and GSK (LSE:GSK) in the FTSE 100

Company calendars are usually set months in advance, long before anyone knows exactly what else will be happening in the market on a given day. This autumn, that has produced an unusual collision. Unilever (LSE:ULVR) is scheduled to publish its third-quarter trading statement on …

Ankur Sharma | 12 October 2026

Why GSK's (LSE:GSK) Q2 core momentum matters ahead of its next FTSE All-Share pharma results

GSK published its second-quarter 2026 results in late July. The company headlined the release by saying it had delivered a solid Q2 core results performance and continued momentum.

Divya Sood | 12 October 2026

What Hikma Pharmaceuticals (LSE:HIK) reiterating its 2026 outlook means for the FTSE All-Share stock

Hikma, a constituent of the FTSE All-Share index in the Pharmaceuticals and Biotechnology sector, published its 2026 interim results and half-year financial report over the summer. In its own announcement, the company said it had delivered a solid first-half performance and reiterated its outlook …

Divya Sood | 12 October 2026

Why Genus (LSE:GNS) launched a £60m buyback after a 35% profit rise: FTSE All-Share update

Genus, a constituent of the FTSE All-Share index in the Pharmaceuticals and Biotechnology sector, released its preliminary results for the year to 30 June 2026 on 10 September 2026, followed by an earnings call the same day.

Divya Sood | 12 October 2026

How ConvaTec's (LSE:CTEC) $200m buyback and 15% dividend rise fit its FTSE All-Share growth targets

ConvaTec reported first-half revenue of $1,232m, up 4.4% year on year. Organic growth was 5.0% excluding InnovaMatrix, its wound biologics product.

Divya Sood | 12 October 2026

What CT Healthcare Trust's (LSE:CTHT) September dividend means for FTSE All-Share income investors

The dividend went ex-dividend on 27 August 2026 and was paid on 18 September. The trust pays dividends twice a year, with a trailing twelve-month dividend equivalent to a yield of about 4.0%.

Divya Sood | 12 October 2026

Why Biotech Growth Trust (LSE:BIOG) NAV rose 86.7% in a year yet lagged in August as FTSE All-Share trust

The August factsheet showed a share price of 1,738.00p and NAV per share of 1,831.00p at the end of the month, a discount of 5.1%. The trust's website put net assets at £347.6m on the same date.

Divya Sood | 12 October 2026
Support

Hi! How can we help you today?

Loading…